Whitehawk Therapeutics Stock Forecast

Stock Price Forecast

The 2 analysts that cover Whitehawk Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $7.50, which forecasts a 82.48% increase in the stock price over the next year. The lowest target is $7.00 and the highest is $8.00.

Price Target: $7.50 (+82.48%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$7.00	$7.50	$8.00	$8.00
Change	+70.32%	+82.48%	+94.65%	+94.65%

Analyst Ratings

The average analyst rating for Whitehawk Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Feb '26	Mar '26	Apr '26
Strong Buy	1	1	1
Buy	0	0	1
Hold	0	0	0
Sell	0	0	0
Strong Sell	0	0	0
Total	1	1	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Reni J. Benjamin Citizens	Citizens	Buy Initiates $8	Buy	Initiates	$8	+94.65%	Apr 16, 2026
Soumit Roy Jones Trading	Jones Trading	Strong Buy Initiates $7	Strong Buy	Initiates	$7	+70.32%	Dec 22, 2025

Financial Forecast

Revenue This Year

n/a

from 7.15M

Revenue Next Year

n/a

EPS This Year

-1.43

from -0.33

EPS Next Year

-1.30

from -1.43

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	1.12M	15.22M	24.35M	25.98M	7.15M	-	-
Revenue Growth	-92.32%	1,258.57%	60.06%	6.69%	-72.50%	-	-
EPS	-12.41	-2.69	-2.44	-2.36	-0.33	-1.43	-1.30
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	7	6

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	n/a	n/a
Avg	n/a	n/a
Low	n/a	n/a

Revenue Growth

Revenue Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2026	2027
High	-1.22	-0.85
Avg	-1.43	-1.30
Low	-1.72	-1.76

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.